期刊文献+

肿瘤化疗与免疫疗法联合应用新进展 被引量:2

Progress in tumor combination treatment of chemotherapy and innnunotherapy
原文传递
导出
摘要 目前应用于恶性肿瘤的治疗方法主要有手术治疗、放疗、化疗以及免疫治疗等。虽然这些方法对肿瘤有一定的治疗作用,但应用单一的治疗手段均有不同的局限性,因此人们不断寻求多种治疗方法的联合应用,以期达到更好地抑制肿瘤生长及改善患者预后的效果。在已探索的各种化疗和免疫治疗的组合中,化疗联合细胞因子、化疗联合肿瘤疫苗、化疗联合免疫佐剂等组合在各种试验及临床应用中均取得可喜效果,有望为人们攻克肿瘤这一难题提供新的途径。 Methods involved in the treatment of malignant tumor are surgical therapy, radiotherapy, chemotherapy and immunothcrapy. Although some effects have been showed in tumor therapy, the limits of single use of those methods can not be avoided. Therefore, combined therapy has been pursued in order to achieve better results. The effects of those combined methods such as chemotherapy combined with cytokine, chemotherapy combined with tumor vaccine, chemotherapy combined with adjuvants have been approved both experimentally and clinically. These results, in some extent, will provide us a new way to fight against tumor.
出处 《国际肿瘤学杂志》 CAS 2010年第5期351-354,共4页 Journal of International Oncology
基金 国家大学生科技创新基金项目(2007066)
关键词 肿瘤 免疫疗法 肿瘤治疗方案 Neoplasms Immunotherapy Antineoplastic protocol
  • 相关文献

参考文献18

  • 1Rescigno M,Avogadri F,Curigliano G.Challenges and prospects of immunotherapy as cancer treatment.Biochim Biophys Acta,2007,1776(1):108-123.
  • 2Tsimberidou AM,O Brien S,Khouri I,et al.Clinical outcomes andprognostic factors in Patients with Richter's syndrome treated withchemotherapy or chemoimmunothempy with or without stem-cell trans-plantation.J Clin Oncol,2006,24(15):2343-2351.
  • 3Schrader AJ,Heidenreich A,Hegele A,et al.Second-line strategiesfor metastatic renal cell carcinoma:classics and novel approaches.J Cancer Res Clin Oncol,2006,132(3):137-149.
  • 4Lygidakis NJ,Sgourakis C,Dedemadi G,et al.Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma.Hepatogastroenterology,2000,47(36):1546-1554.
  • 5Hoffmann K,Mehrle S,Schmidt J,et al.Interferon-alpha restitutes the chemosensitivity in pancreatic cancer.Anticancer Res,2008,28 (3A):1499-1507.
  • 6Cvetkovic RS,Perry CM.Rituximab:a review of its use in nonHodgkin's lymphoma and chronic lymphocytic leukaemia.Drugs,2006,66(6):791-820.
  • 7Su CF,Tsai HJ,Kuo C,et al.Primary non-Hodgkin's lymphoma of the uterus,cervix and parametrium treated by combined immunochemotherapy.J Obstet Gynaecol Res,2008,34(4 Pt 2):749-753.
  • 8Boehme V,Schmitz N,Zeynalova S,et al.,CNS events in elderly patients with aggressive lymphoma treated with modem chemotherapy (CHOP-14) with or without rituximab:an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).Blood,2009,113(17):38% -3902.
  • 9Schulz H,Bohlius JF,TreUe S,et al.,Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma:a systematic review and meta-analysis.J Nail Cancer Inst,2007,99(9):706-714.
  • 10Mey UJ,Olivier! A,Orlopp KS,et al.,DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma:a matched-pair analysis.Leuk Lymphoma,2006,47(12):2558-2566.

二级参考文献9

共引文献2

同被引文献18

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部